NFXBio: Deal or Die – A Guide to TechBio Business Development and Strategy

There are two parts to building a bioplatform: you have to focus on the science, then you have to think about the business side. When do you partner? When do you develop your own products? How can you determine the real value of a deal? How do you build a strategic network? What avenues are Founders overlooking right now? These are questions our companies ask us all the time. Today, Head of NFXBio Omri Amirav-Dory, Yael Gruenbaum-Cohen, a venture partner at aMoon Fund, and Peter Nell, former Chief Business Officer and head of Therapeutics at Mammoth Biosciences, are charting a roadmap for successful bioplatform business development. (0:00) Introduction by Omri Amirav-Drory and Guest Introductions: Peter Neil and Yael Gruenbaum-Cohen (4:06) Discussion on NFX's Investment Focus and the Role of Business Development in Startups (11:33) Importance of Strategic Partnerships and the Right Deals for Company Growth (17:19) Building Trust and Relationships in Business Development, Importance of Patience (23:13) The Role of Soft Skills, Evidence Required for Partnerships and the Relevance of Animal Models in Funding (30:04) Common Mistakes Founders Make During Deal-Making and a Hypothetical Case Study Discussion (36:29) The Potential and Challenges of Commercializing Technology as a Service in Platform Companies (38:48) The Dilemma of Balancing Pipeline Advancement and Financial Opportunities in Startups (41:00) Exploring New Avenues for Business Development: Partnering and Competition (43:49) Final Thoughts on Business Development in the Current Funding Climate and Closing Remarks by Omri Amirav-Drory